Our Company
An innovative spin-out, backed by serious expertise.
ClotProtect are a UK therapeutics spin-out from the University of Leeds. Led by an integrated and experienced project team comprising of world leading scientific experts, key opinion leaders in clinical guidance and trials, and ex-pharma drug discovery advisors, we are currently in preclinical development aiming to soon identify a clinical drug candidate.
$4BN
potential market opportunity
Meet our world-leading drug discovery team
Prof. Helen Philippou
CEO, Co-Founder, Biology Lead
Professor of Translational Medicine, Chair of the International Society of Fibrinolysis and Proteolysis.
Dr. Richard Foster
Co-Founder, Chemistry Lead
Associate Professor of Medicinal Chemistry, Former Industry project leader.
Ned Wakeman
CBO & Co-Founder
Investment banking raising >£600m. Supported the creation & growth of over 200 life science companies.
Dr. Genghis Lloyd-Harris
Chairman
Ex-partner Abingworth >20 years. Extensive board and company building experience from early research through preclinical and clinical.
Dr. Nigel Brooks
CDO
Former executive level leader in large pharma and biotech sectors. Extensive drug discovery and development experience.
Mark Hollingworth
CFO
CFO pharma/biotech, coordinating multiple strategic equity financing rounds / in-licensing/out-licensing/investment/divestment and business
Pip Wolfenden
Project Manager
Pip is an experienced PMP certified Project Manager with a scientific and clinical development background. She spent 20 years at AstraZeneca before moving to a consulting role.
Advised by clinical key opinion leaders
Prof. Beverley Hunt
KOL: Anti-fibrinolytics
Clinical lead thrombosis & Haemostasis KOL, founder of Thrombosis UK. Advisor to NICE on anti-fibrinolytic guidelines.
Dr. Nicola Curry
KOL: Trauma
Consultant Haematologist, Oxford Haemophilia & Thrombosis Centre, Founding member of International Trauma Research Network & led several interventional trials.